Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
PAVmed Inc.
Craig Kallman, a major shareholder of PAVmed Inc., has filed a SCHEDULE 13G/A to report changes in beneficial ownership. This filing provides an update on the investor's equity position in the company.…more
PAVmed Inc.
PAVmed's subsidiary, Lucid Diagnostics, has completed a $15 million offering of Series C Convertible Preferred Stock to accredited investors. The transaction involved the sale of 15,000 shares at a price of $1,000 per share, with a registration rights agreement executed to cover the resale of common stock issuable upon conversion.…more
1 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Lucid Diagnostics Secures Medicare Payments and $15M Private Placement
Lucid Diagnostics has begun receiving Medicare payments for its EsoGuard test and closed a $15 million private placement of Series C convertible preferred stock. The proceeds are intended to accelerate commercial operations, though the conversion terms introduce potential equity dilution.…more
●●●●●●●● ●●●●● ●●●●●●
PAVmed has entered into an agreement to sell up to $9.4 million of its common stock through an at-the-market offering. This capital-raising move may lead to shareholder dilution, which is typically viewed as a bearish signal for the stock price.…more
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.